Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efalizumab in Psoriasis Non-Responders to Anti-TNF
NCT00336973Phase 4Completed
- Sponsor
- Genentech
- Start
- May 2006
- Primary completion
- Feb 2008
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
01
Overview
Phase 4, open-label, single-arm trial of efalizumab in plaque psoriasis, sponsored by Genentech. Primary endpoint: Proportion of Subjects With a Physician's Global Assessment (PGA) Rating of Clear (0), Almost Clear (1), or Mild (2) at Day 84. Started May 2006; status: completed.
02
Drugs
efalizumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT00336973.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00336973.